Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a leading pharmaceutical company with strong financials and a diverse portfolio of products targeting various therapeutic areas. The company's solid second-quarter performance beat analyst expectations and continued growth seen in its key products, such as tirzepatide, Mounjaro, Zepbound, Jardiance, Trulicity, Taltz, and Olumiant. Additionally, Eli Lilly's focus on expanding internationally and entering new markets, along with its commitment to sustainability and diversity in clinical trials, indicates a strong long-term outlook for the company.

Bears say

Eli Lilly is expected to face slowing growth in their key cancer and cardiometabolic products, as well as potential competition and pricing pressure. They are also at risk for underperforming in their pipeline products, and may face headwinds in the broader sector. Despite strong performance in their Mounjaro product, their overall stock outlook is negative due to potential challenges in multiple product segments and pricing.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,302.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,302.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.